Can I Take St. John's Wort with AOD-9604?

The Short Answer on This Combination

There is no published pharmacokinetic study examining AOD-9604 and St. John's Wort together. What we do have is solid mechanistic science on each agent separately, and that science points to a potential one-directional pharmacokinetic interaction driven by St. John's Wort's potent induction of the cytochrome P450 3A4 enzyme system.

AOD-9604 is a 16-amino-acid synthetic peptide derived from the C-terminal region of human growth hormone. Because it is a peptide, its primary metabolic pathway involves proteolytic degradation rather than hepatic CYP enzyme metabolism. That distinction matters, and it is covered in detail below.

What Is AOD-9604 and How Does Your Body Process It?

AOD-9604, also called HGH fragment 176-191, mimics the lipolytic region of human growth hormone without the insulin-like growth factor-1 (IGF-1) stimulating activity of the full hormone. Preclinical data showed it reduced adipose tissue in animal models, and it reached Phase II/III clinical trials for obesity in the early 2000s under the brand name Metabolase before development was discontinued. Regulatory and trial background is archived at the National Library of Medicine.

How AOD-9604 Is Metabolized

Peptides like AOD-9604 are not primarily metabolized by CYP450 enzymes. They are cleaved by circulating peptidases, serum proteases, and renal filtration. This peptide metabolic pathway is well established in the pharmacokinetics of therapeutic peptide literature and is distinct from the hepatic oxidative metabolism that governs most small-molecule drugs.

This means that if St. John's Wort induces CYP3A4, it would not directly accelerate the breakdown of AOD-9604 itself through that enzyme pathway. The pharmacokinetic interaction, in the classical CYP3A4 sense, is likely low for AOD-9604 specifically.

Why the Risk Is Not Zero

The concern does not disappear, for two reasons.

First, many women taking AOD-9604 through a 503A compounding pharmacy are also taking other compounds in the same protocol, including thyroid hormones, oral contraceptives, or other peptides that DO rely on CYP3A4 metabolism. St. John's Wort would interact with those co-administered agents even if it leaves AOD-9604 largely unaffected.

Second, a pharmacodynamic overlap exists. Both AOD-9604 and St. John's Wort are used, in different ways, to influence mood, energy, and body composition. St. John's Wort's active constituents, hypericin and hyperforin, affect serotonin, dopamine, and norepinephrine reuptake. AOD-9604 operates on beta-3 adrenergic receptors and fatty acid metabolism pathways. The additive effects on adrenergic signaling have not been systematically studied in women.

St. John's Wort: CYP3A4 Induction Explained

St. John's Wort (Hypericum perforatum) is the most clinically significant herbal CYP3A4 inducer known. A landmark study published in The Lancet in 2000 demonstrated that St. John's Wort reduced plasma cyclosporine levels by an average of 52% in organ transplant recipients, triggering acute rejection episodes. This was the event that forced widespread regulatory attention to herbal-drug interactions.

How Induction Works

Hyperforin, the primary constituent responsible for CYP3A4 induction, activates pregnane X receptor (PXR), a nuclear receptor that upregulates transcription of CYP3A4, CYP2C9, and P-glycoprotein (P-gp). Research published in Drug Metabolism and Disposition confirmed that hyperforin concentrations as low as 0.1 micromolar are sufficient to activate PXR.

The practical result: any drug or compound that relies on CYP3A4 for its metabolism will be cleared faster than expected when St. John's Wort is taken concurrently. Plasma levels drop. Clinical effect diminishes.

Onset and Reversal Timeline

Induction is not immediate. Studies show that measurable CYP3A4 induction begins within 3 to 7 days of regular St. John's Wort use at standard doses (300 mg three times daily of an extract standardized to 0.3% hypericin). Full induction is reached by approximately 14 days. After stopping St. John's Wort, the enzyme activity returns to baseline over 1 to 2 weeks as existing enzyme protein is degraded and not replaced.

This means that stopping St. John's Wort the day before starting a new protocol does not protect you. A washout period of at least 14 days is the standard clinical recommendation before introducing CYP3A4-sensitive agents.

Women-Specific Pharmacology: Why This Matters More for You

Hormonal Contraception: A Direct and Documented Risk

This is the interaction that has the most clinical evidence and the highest stakes for women. The FDA issued a public health advisory noting that St. John's Wort reduces plasma ethinyl estradiol and norethindrone levels in women taking combined oral contraceptives. A study in Clinical Pharmacology and Therapeutics found breakthrough bleeding increased significantly and contraceptive hormone exposure was reduced by 13-15% in women taking St. John's Wort concurrently.

If you are taking any hormonal contraceptive, including the pill, the patch, the hormonal IUD, or the vaginal ring, and you are also considering St. John's Wort for mood, PMS, or perimenopause symptoms, you need to know this risk explicitly. Backup contraception or an alternative antidepressant is warranted.

Women on AOD-9604 protocols who also use hormonal contraception are in a three-way interaction territory that has never been formally studied.

Menstrual Cycle and Hormonal Context

Across the reproductive years, CYP3A4 activity itself fluctuates with the menstrual cycle. Research published in Clinical Pharmacology and Therapeutics demonstrated that CYP3A4 activity is modestly higher in the luteal phase compared to the follicular phase, driven by progesterone's weak PXR activation. This means the magnitude of any St. John's Wort induction effect may vary slightly across your cycle. For most women this variation is clinically minor, but it is a real phenomenon that has been largely ignored in trials conducted primarily in men.

Perimenopause and Menopause

St. John's Wort is commonly used by women in perimenopause for mood disturbance and mild depression, which are highly prevalent in this stage. A Cochrane review found St. John's Wort superior to placebo for mild to moderate depression, with a side-effect profile comparable to low-dose antidepressants. Many perimenopausal women are also exploring peptide protocols for body composition and energy. The likelihood of co-use in this demographic is not trivial.

Perimenopausal women may also be on hormone therapy (HT). Estradiol is a CYP3A4 substrate. The Menopause Society (formerly NAMS) clinical practice recommendations caution that herbal CYP3A4 inducers, including St. John's Wort, may reduce circulating estradiol levels in women on oral hormone therapy, potentially blunting efficacy.

A practical framework for women on multiple agents: before adding St. John's Wort to any regimen that includes hormonal contraception, hormone therapy, thyroid medication, or peptide protocols, map each agent to its metabolic pathway. Agents cleared by CYP3A4, CYP2C9, or P-gp are at risk of reduced exposure. Peptides metabolized proteolytically, like AOD-9604, carry lower direct risk but remain embedded in a broader hormonal context where St. John's Wort causes documented harm.

PCOS Considerations

Women with PCOS are disproportionately represented among those seeking body composition interventions like AOD-9604. Many also use metformin, oral contraceptives for cycle regulation, or spironolactone for androgen suppression. St. John's Wort induces CYP3A4 and P-gp; spironolactone is a CYP3A4 substrate. Published interaction data confirms that CYP3A4 induction can meaningfully reduce spironolactone plasma concentrations, which could reduce its androgenic effect in women relying on it for hair loss or acne control.

Pregnancy and Lactation Safety

Pregnancy: Avoid Both Agents

AOD-9604 has no human pregnancy safety data. It has not been assigned a formal FDA pregnancy category because it has never been FDA-approved. Animal developmental toxicity studies sufficient for regulatory evaluation were not completed before clinical development stopped. Growth hormone-related peptides, as a class, can influence IGF-1 signaling, placental function, and fetal growth. Until adequate safety data exists, this peptide should not be used during pregnancy or while actively trying to conceive.

St. John's Wort has limited but concerning human pregnancy data. A prospective cohort study found no increased rate of major malformations in women who took St. John's Wort during the first trimester compared to controls, but neonatal complications including colic, drowsiness, and lethargy were reported at higher rates when exposure continued into the third trimester. ACOG advises against routine use of herbal supplements during pregnancy without documented safety data, and St. John's Wort falls into that category.

Lactation: Avoid Both Agents

St. John's Wort constituents, including hypericin, transfer into human breast milk. A study in the American Journal of Obstetrics and Gynecology detected hypericin in breast milk and in infant plasma of nursing mothers taking therapeutic doses. Infant exposure was low but measurable, and the long-term developmental implications are unknown.

AOD-9604 has zero published lactation transfer data. The peptide's small size (16 amino acids) and relative stability suggest it could survive gastric digestion in a nursing infant, but this is speculative extrapolation. The precautionary position is to avoid it during lactation.

If you are postpartum and struggling with mood, energy, or body weight, please discuss alternatives with your provider that have established safety profiles in this stage.

Contraception Requirement

Because St. John's Wort reduces oral contraceptive efficacy, women of reproductive age who take it must use a non-hormonal backup method (copper IUD or barrier method) or an alternative form of contraception not reliant on CYP3A4-metabolized hormones. This is not optional guidance. The FDA label-level interaction warning for St. John's Wort and hormonal contraceptives has been in place since 2000.

Who This Combination May Be Appropriate For vs. Not

Lower-Risk Scenarios

You may face lower direct pharmacokinetic risk from combining AOD-9604 with St. John's Wort if all of the following apply: you are not taking any CYP3A4-metabolized medications (no oral contraceptives, no hormone therapy, no spironolactone, no thyroid compounded formulas using CYP-sensitive excipients), you are not pregnant or lactating, and your provider is fully aware of both agents and has reviewed your complete medication and supplement list.

Even then, the pharmacodynamic interaction on adrenergic and serotonergic pathways remains uncharacterized.

Higher-Risk Scenarios

Do not take St. John's Wort concurrently with AOD-9604 without explicit provider review if you are:

• On any hormonal contraceptive
• Using hormone therapy for perimenopause or menopause
• Taking spironolactone for PCOS, acne, or hair loss
• On levothyroxine or any compounded thyroid preparation
• Pregnant, trying to conceive, or breastfeeding
• Using other peptides or compounds in the same protocol that have CYP3A4 metabolism

The Evidence Gap You Deserve to Know About

Women have been consistently under-represented in pharmacokinetic drug-interaction research. The St. John's Wort CYP3A4 induction literature is drawn primarily from studies in male subjects or mixed-sex populations where female-specific subgroup analyses were not reported. The FDA's Drug Trials Snapshots program has documented this gap across therapeutic categories. The honest position is that we are extrapolating male-derived pharmacokinetic principles to women's bodies, while knowing that CYP3A4 activity, hormonal milieu, and peptide clearance all differ by sex and life stage.

Monitoring and Practical Guidance

If you are currently taking both agents and did not know about this interaction, here is what to do.

First, make a complete list of every medication, hormone, and supplement you are taking. Second, share that list with the prescribing or supervising clinician for your AOD-9604 protocol. Third, if you are on any CYP3A4-sensitive medication, ask whether your current dose is still achieving its intended effect, particularly if symptoms have changed since starting St. John's Wort.

For mood support as an alternative to St. John's Wort in women on complex protocols, options with fewer drug interactions include magnesium glycinate at 200-400 mg daily, which showed modest benefit for anxiety and PMS in a double-blind trial, or saffron extract (Crocus sativus, 30 mg/day), which meta-analysis published in Human Psychopharmacology found superior to placebo for mild-to-moderate depression without clinically significant CYP interactions.

If St. John's Wort is genuinely needed, the standard therapeutic dose is 300 mg three times daily of an extract standardized to 0.3% hypericin and at minimum 1-4% hyperforin. Lower-hyperforin extracts (below 0.1-0.2% hyperforin) may induce CYP3A4 less aggressively, though this is not a reliable safety strategy and has not been tested with AOD-9604.

A washout of 14 days from St. John's Wort is needed before introducing CYP3A4-sensitive agents, or before relying again on hormonal contraception after stopping St. John's Wort.

AOD-9604's Regulatory Status and What It Means for Interaction Research

AOD-9604 is not FDA-approved for any indication. It is available in the United States only through 503A compounding pharmacies, which produce patient-specific preparations without the clinical trial requirements that accompany drug approval. This regulatory status means that the drug interaction database entries that exist for approved pharmaceuticals simply do not exist for AOD-9604. The FDA's position on compounded peptides makes clear that safety and interaction data requirements are substantially reduced compared to the NDA pathway.

The clinical trial that brought AOD-9604 closest to approval, the METAOD003 and related Metabolase studies, evaluated metabolic endpoints but did not systematically examine drug interactions with herbal supplements. Published results from the Phase IIb trial focused on adipose outcomes and blood glucose, not on pharmacokinetic profiling in women on concurrent supplements.

This is not a reason to dismiss the compound. It is a reason to be clear-eyed: the interaction data that would normally inform your decision simply does not exist for this pairing. Clinical judgment based on mechanism is the best available tool.